Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy

Introduction of immune checkpoint inhibitors (ICIs) has led to significant improvements in the treatment of multiple malignancies. Anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) are two essential ICIs that have been FDA approved since 2011. As the use...

Descripción completa

Detalles Bibliográficos
Autores principales: Balakrishna, Pragathi, Villegas, Augusto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698791/
https://www.ncbi.nlm.nih.gov/pubmed/29250451
http://dx.doi.org/10.1155/2017/5063405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698791/
https://www.ncbi.nlm.nih.gov/pubmed/29250451
http://dx.doi.org/10.1155/2017/5063405

Ejemplares similares